Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REal-world Utilization and Treatment Target ACHievement With Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis in China

NCT06421740 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06421740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06421740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REal-world Utilization and Treatment Target ACHievement With Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis in China
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
June 7, 2024
Completion date
May 25, 2026
Enrollment
1,000 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis